Advanced search
Publication Cover
Current Medical Research and Opinion Volume 26, 2010 - Issue 5
Submit an article Journal homepage
948
Views
25
CrossRef citations to date
0
Altmetric
Commentary

Biosimilars: controversies as illustrated by rhGH

Paul J. Declerck Faculty of Pharmaceutical Sciences, K.U. Leuven, Leuven, BelgiumCorrespondence[email protected]
,
Feyza Darendeliler Istanbul Faculty of Medicine, Istanbul, Turkey
,
Miklós Góth Second Department of Internal Medicine, State Health Centre, Budapest, Hungary
,
Stanislava Kolouskova University Hospital Motol, Prague, Czech Republic
,
Ioana Micle University of Medicine and Pharmacy Victor Babes, Timisoara, Romania; Clinical Emergency Hospital for Children Louis Turcanu, Timisoara, Romania
,
Cees Noordam Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands
,
Valentina Peterkova Endocrinological Scientific Centre, Russian Academy of Science, Moscow, Russian Federation
,
Natalia N. Volevodz Endocrinological Scientific Centre, Russian Academy of Science, Moscow, Russian Federation
,
Jiřina Zapletalová University Hospital and Faculty of Medicine, Palacky University, Olomouc, Czech Republic
&
Michael B. Ranke University Children’s Hospital, Tübingen, Germany
 show all
Pages 1219-1229 | Accepted 22 Feb 2010, Published online: 22 Mar 2010

Citations (25)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Paul Declerck, Håkan Mellstedt & Silvio Danese. (2015) Biosimilars – terms of use. Current Medical Research and Opinion 31:12, pages 2325-2330.
Read now
Paul J Declerck & Steven Simoens. (2012) A European perspective on the market accessibility of biosimilars. Biosimilars 2, pages 33-40.
Read now
Bhupinder Singh Sekhon & Vikrant Saluja. (2011) Biosimilars: an overview. Biosimilars 1, pages 1-11.
Read now

Articles from other publishers (22)

Basanta Kumara Behera. 2023. Conceptual Development of Industrial Biotechnology for Commercial Production of Vaccines and Biopharmaceuticals. Conceptual Development of Industrial Biotechnology for Commercial Production of Vaccines and Biopharmaceuticals 121 142 .
Huaipan Jiang, Jian Wang, Weilin Cong, Yihe Huang, Morteza Ramezani, Anup Sarma, Nikolay V. Dokholyan, Mehrdad Mahdavi & Mahmut T. Kandemir. (2022) Predicting Protein–Ligand Docking Structure with Graph Neural Network. Journal of Chemical Information and Modeling 62:12, pages 2923-2932.
Crossref
Xiang Yan, Shan Jiang, Ying Lou & Zhiguang Zhou. (2021) Comparable efficacy and safety between LY2963016 insulin glargine and insulin glargine (Lantus®) in Chinese patients with type 1 diabetes: A phase III , randomized, controlled trial . Diabetes, Obesity and Metabolism 23:10, pages 2226-2233.
Crossref
Favour Danladi Makurvet. (2021) Biologics vs. small molecules: Drug costs and patient access. Medicine in Drug Discovery 9, pages 100075.
Crossref
Pınar Tunçbilek Özmanevra, Füsun Yıldız & Sarah K. Wise. 2021. Challenges in Rhinology. Challenges in Rhinology 377 386 .
Hans C. Ebbers. 2020. Biologics, Biosimilars, and Biobetters. Biologics, Biosimilars, and Biobetters 109 124 .
Francisco Javier Ampudia-Blasco. (2020) Biosimilars and Novel Insulins. American Journal of Therapeutics 27:1, pages e52-e61.
Crossref
Steven R. Feldman, Jerry Bagel & Shahla Namak. (2018) Biosimilars for Immune-Mediated Chronic Diseases in Primary Care: What a Practicing Physician Needs to Know. The American Journal of the Medical Sciences 355:5, pages 411-417.
Crossref
Antonello Di Paolo & Elena Arrigoni. (2018) Generic Substitution of Orphan Drugs for the Treatment of Rare Diseases: Exploring the Potential Challenges. Drugs 78:4, pages 399-410.
Crossref
M. Davies, D. Dahl, T. Heise, J. Kiljanski & C. Mathieu. (2017) Introduction of biosimilar insulins in Europe. Diabetic Medicine 34:10, pages 1340-1353.
Crossref
Melda Comert Ozkan, Fahri Sahin & Guray Saydam. (2015) Peripheral blood stem cell mobilization from healthy donors. Transfusion and Apheresis Science 53:1, pages 13-16.
Crossref
Rossella Belleli, Roland Fisch, Didier Renard, Heike Woehling & Sandro Gsteiger. (2015) Assessing switchability for biosimilar products: modelling approaches applied to children's growth. Pharmaceutical Statistics 14:4, pages 341-349.
Crossref
Martina WeisePekka KurkiElena Wolff-HolzMarie-Christine BielskyChristian K. Schneider. (2014) Biosimilars: the science of extrapolation. Blood 124:22, pages 3191-3196.
Crossref
Martina WeiseMarie-Christine BielskyKaren De SmetFalk EhmannNiklas EkmanThijs J. GiezenIordanis GravanisHans-Karl HeimEsa HeinonenKowid HoAlexandre MoreauGopalan NarayananNanna A. KruseGabriele ReichmannRobin ThorpeLeon van Aerts, Camille VleminckxMeenu WadhwaChristian K. Schneider. (2012) Biosimilars: what clinicians should know. Blood 120:26, pages 5111-5117.
Crossref
Abdol Majid Cheraghali. (2012) Biosimilars; a unique opportunity for Iran national health sector and national pharmaceutical industry. DARU Journal of Pharmaceutical Sciences 20:1.
Crossref
Hans C Ebbers, Stacy A Crow, Arnold G Vulto & Huub Schellekens. (2012) Interchangeability, immunogenicity and biosimilars. Nature Biotechnology 30:12, pages 1186-1190.
Crossref
Steven Simoens, Gilbert Verbeken & Isabelle Huys. (2012) Biosimilars and market access: a question of comparability and costs?. Targeted Oncology 7:4, pages 227-231.
Crossref
Hans C. Ebbers, Toine Pieters, Hubert G. Leufkens & Huub Schellekens. (2012) Effective pharmaceutical regulation needs alignment with doctors. Drug Discovery Today 17:3-4, pages 100-103.
Crossref
Paul Saenger. (2011) Biosimilar Growth Hormone. The Indian Journal of Pediatrics 79:1, pages 92-98.
Crossref
S. Simoens, G. Verbeken & I. Huys. (2011) Market access of biosimilars: not only a cost issueL’accès au marché par les biosimilaires: pas seulement un problème de coût. Oncologie 13:5, pages 218-221.
Crossref
Heather A Myler, Allison Given, Karen Kolz, Johanna R Mora & George Hristopoulos. (2011) Biotherapeutic bioanalysis: a multi-indication case study review. Bioanalysis 3:6, pages 623-643.
Crossref
Kyriaki S. Alatzoglou & Mehul T. Dattani. (2010) Genetic causes and treatment of isolated growth hormone deficiency—an update. Nature Reviews Endocrinology 6:10, pages 562-576.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.